Cargando…

Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes

Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF). We employed cell-specific differentiation protocols and optical mapping to investigate the effects of IB an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafaattalab, Sanam, Lin, Eric, Christidi, Effimia, Huang, Haojun, Nartiss, Yulia, Garcia, Analucia, Lee, Jeehon, Protze, Stephanie, Keller, Gordon, Brunham, Liam, Tibbits, Glen F., Laksman, Zachary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524928/ https://www.ncbi.nlm.nih.gov/pubmed/31031187 http://dx.doi.org/10.1016/j.stemcr.2019.03.011

Ejemplares similares

RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes
por: Huang, Haojun, et al.
Publicado: (2022)

Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes
por: Christidi, Effimia, et al.
Publicado: (2020)

Modeling Atrial Fibrillation using Human Embryonic Stem Cell-Derived Atrial Tissue
por: Laksman, Zachary, et al.
Publicado: (2017)

Drug screening platform using human induced pluripotent stem cell‐derived atrial cardiomyocytes and optical mapping
por: Gunawan, Marvin G., et al.
Publicado: (2020)

Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes
por: Goldfracht, Idit, et al.
Publicado: (2020)

Regulated cell death pathways in doxorubicin-induced cardiotoxicity
por: Christidi, Effimia, et al.
Publicado: (2021)

Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation
por: Yang, Xinyu, et al.
Publicado: (2020)

Reply to ‘Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?’
por: Shiti, Assad, et al.
Publicado: (2021)

Mechanisms of Arrhythmogenicity of Hypertrophic Cardiomyopathy-Associated Troponin T (TNNT2) Variant I79N
por: Shafaattalab, Sanam, et al.
Publicado: (2021)

How to Manage Atrial Fibrillation Secondary to Ibrutinib
por: Essa, Hani, et al.
Publicado: (2021)

High incidence of atrial fibrillation in patients treated with ibrutinib
por: Baptiste, Florian, et al.
Publicado: (2019)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
por: Kapoor, Ridhima, et al.
Publicado: (2021)

5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation
por: Shuai, Wei, et al.
Publicado: (2023)

Using human induced pluripotent stem cell-derived cardiomyocytes to understand the mechanisms driving cardiomyocyte maturation
por: Hamledari, Homa, et al.
Publicado: (2022)

Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
por: Khalid, Sidra, et al.
Publicado: (2018)

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
por: Stühlinger, Markus C., et al.
Publicado: (2019)

Quinidine effective for the management of ventricular and atrial arrhythmias associated with Brugada syndrome
por: Halperin, Laura, et al.
Publicado: (2018)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
por: Reda, Gianluigi, et al.
Publicado: (2018)

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
por: Caldeira, Daniel, et al.
Publicado: (2019)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
por: Tuomi, Jari M., et al.
Publicado: (2021)

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
por: Brown, Jennifer R., et al.
Publicado: (2017)

Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion
por: Berti, Sergio, et al.
Publicado: (2022)

Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion
por: Jeelani, Hafiz, et al.
Publicado: (2022)

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes
por: Maillet, Agnes, et al.
Publicado: (2016)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Generation of mature compact ventricular cardiomyocytes from human pluripotent stem cells
por: Funakoshi, Shunsuke, et al.
Publicado: (2021)

Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic β-Cell Dysfunction
por: Vergeer, Menno, et al.
Publicado: (2010)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Ibrutinib-Induced Skin Rash
por: Kirar, Sudhir, et al.
Publicado: (2021)

Ibrutinib: Pneumonitis: case report
Publicado: (2021)

Arrhythmia Patterns in Patients on Ibrutinib
por: Fazal, Muhammad, et al.
Publicado: (2022)

Mechanisms of Pathogenicity of Hypertrophic Cardiomyopathy-Associated Troponin T (TNNT2) Variant R278C(+/−) During Development
por: Shafaattalab, Sanam, et al.
Publicado: (2023)

Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib
por: Avalon, Juan Carlo, et al.
Publicado: (2021)

A Population-Based Study of Unexplained/Lone Atrial Fibrillation: Temporal Trends, Management, and Outcomes
por: Roston, Thomas M., et al.
Publicado: (2021)

Profound Sinoatrial Arrest Associated with Ibrutinib
por: Mathur, Kanupriya, et al.
Publicado: (2017)

Ibrutinib‐induced severe liver injury
por: Nandikolla, Amara G., et al.
Publicado: (2017)

Electrocardiographic Changes Associated With Ibrutinib Exposure
por: Fradley, Michael G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_31i65c71aiogu26jorja0sovn4